neurogram.wordpress.com
mAbMEN: It’s Not Over | neurogram
https://neurogram.wordpress.com/2015/07/23/mabmen-its-not-over
The Blog for NeuroPerspective. Walking It Back on Axovant. MAbMEN: It’s Not Over. July 23, 2015. Eli Lilly: Experimental Alzheimer’s drug shows some benefit (AP). Eli Lilly’s Solanezumab Is the Alzheimer’s Drug Equivalent of the Internet Dress (TheStreet). Lilly says drug slows Alzheimer’s in patients with mild disease (Reuters). Lilly’s Alzheimer’s Drug May Slow Patients’ Decline (The Wall Street Journal). Biogen, Lilly Alzheimer’s Data Spark Street Debate (Investor’s Business Daily). You are commenting...
neurogram.wordpress.com
Walking It Back on Axovant | neurogram
https://neurogram.wordpress.com/2015/07/09/walking-it-back-on-axovant
The Blog for NeuroPerspective. MAbMEN: It’s Not Over →. Walking It Back on Axovant. July 9, 2015. Subscribers are aware that we have not been unreservedly enthused about Axovant. Its 5HT-6 drug for Alzheimer’s (licensed from GSK. The question was, in the words of the. That is on Axovant, they should have been more forthcoming in addressing what could easily be perceived as unbridled nepotism. So, it is now up to Axovant’s staff to earn their remuneration packages, and up to Axovant to justify the hefty i...
neurogram.wordpress.com
Naurex | neurogram
https://neurogram.wordpress.com/2015/07/27/naurex
The Blog for NeuroPerspective. MAbMEN: It’s Not Over. She Loves Me, She Loves Me Not →. July 27, 2015. Over the weekend, Naurex announced that it had been acquired by Allergan. For $560 million plus undisclosed milestones; Allergan is focused upon Naurex’s two clinical-stage Rapid-Acting-Antidepressant candidates, IV rapastinel/GlyX-13, and orally-bioavailable NRX-1074. NIR has been following this particular technology since 2003, through its iterations as Nyxis Neurotherapies. MAbMEN: It’s Not Over.
neurogram.wordpress.com
NeuroPerspective | neurogram
https://neurogram.wordpress.com/author/neurogram
The Blog for NeuroPerspective. Academic Opioid Leapfrogs Field Perhaps. August 20, 2016. Nature was the venue (8/18/16) for the publication of a paper from academic collaborators at UCSF, Stanford, UNC, Friedrich-Alexander-Universität Erlangen-Nürnberg, and Parelcus Medical University, a paper that reported the development of a highly refined, selective mu opioid agonist that in animal … Continue reading →. July 12, 2016. Purdue’s Potemkin Village of Addiction-Prevention: Make Them Pay. July 11, 2016.
neurogram.wordpress.com
neurogram | The Blog for NeuroPerspective | Page 2
https://neurogram.wordpress.com/page/2
The Blog for NeuroPerspective. Newer posts →. Http:/ www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees. March 30, 2016. Questions and Answers Regarding Advisory Committee Membership. What is an FDA Advisory Committee? How does an individual become a member of an FDA advisory committee? What are the qualifications of an advisory committee member? Persons nominated as scientific members must be technically qualified experts in their field and have experience interpreting complex data. While we wou...
neurogram.wordpress.com
Sages and Mariners | neurogram
https://neurogram.wordpress.com/2015/06/10/sages-and-mariners
The Blog for NeuroPerspective. Walking It Back on Axovant →. June 10, 2015. The report from SAGE Therapeutics. 2014) The results obtained by ketamine, JNJ. 8216;s esketamine, and Naurex. 8216;s GlyX-13 in major depression (not associated with the post-partum period) also have shown that rapid antidepressant impact is achievable. This brings us to Marinus Pharmaceuticals. This entry was posted in Biotech. Walking It Back on Axovant →. Leave a Reply Cancel reply. Enter your comment here. You are commenting...
